Janus Henderson Group PLC Boosts Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Janus Henderson Group PLC boosted its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 7.7% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,588,571 shares of the medical equipment provider’s stock after buying an additional 257,022 shares during the period. Janus Henderson Group PLC owned approximately 5.16% of Lantheus worth $393,844,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Signaturefd LLC boosted its position in shares of Lantheus by 40.5% during the 3rd quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock worth $35,000 after purchasing an additional 92 shares in the last quarter. Silverberg Bernstein Capital Management LLC boosted its position in shares of Lantheus by 0.4% during the 2nd quarter. Silverberg Bernstein Capital Management LLC now owns 22,843 shares of the medical equipment provider’s stock worth $1,834,000 after purchasing an additional 100 shares in the last quarter. UMB Bank n.a. boosted its position in shares of Lantheus by 42.1% during the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock worth $47,000 after purchasing an additional 126 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of Lantheus by 45.5% during the 3rd quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider’s stock worth $51,000 after purchasing an additional 146 shares in the last quarter. Finally, Nisa Investment Advisors LLC boosted its position in shares of Lantheus by 4.5% during the 2nd quarter. Nisa Investment Advisors LLC now owns 6,643 shares of the medical equipment provider’s stock worth $533,000 after purchasing an additional 287 shares in the last quarter. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have commented on LNTH. StockNews.com lowered shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. Truist Financial restated a “buy” rating and set a $120.00 target price (down from $135.00) on shares of Lantheus in a research report on Friday, November 8th. JMP Securities decreased their price objective on shares of Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a research report on Thursday, November 7th. Finally, Redburn Atlantic started coverage on shares of Lantheus in a research report on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 price objective on the stock. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $125.71.

Lantheus Trading Down 1.2 %

Shares of LNTH stock opened at $88.51 on Wednesday. The firm has a 50-day moving average price of $100.44 and a 200 day moving average price of $97.49. Lantheus Holdings, Inc. has a twelve month low of $50.20 and a twelve month high of $126.89. The company has a market capitalization of $6.15 billion, a price-to-earnings ratio of 14.73 and a beta of 0.45.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.